{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:57:29Z","timestamp":1772261849556,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.bulcan.2023.10.007","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T07:30:31Z","timestamp":1702279831000},"page":"51-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Place des th\u00e9rapies innovantes dans la prise en charge des cancers du col de l\u2019ut\u00e9rus"],"prefix":"10.1016","volume":"111","author":[{"given":"Diana","family":"Bello Roufai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bulcan.2023.10.007_bib0170","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36\u00a0Cancers in 185\u00a0Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"10.1016\/j.bulcan.2023.10.007_bib0175","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.ejca.2015.07.022","article-title":"Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5\u00a0study","volume":"51","author":"Sant","year":"2015","journal-title":"Eur J Cancer"},{"issue":"20","key":"10.1016\/j.bulcan.2023.10.007_bib0180","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med."},{"issue":"8","key":"10.1016\/j.bulcan.2023.10.007_bib0185","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved Survival with Bevacizumab in Advanced Cervical Cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2023.10.007_bib0190","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with Cemiplimab in Recurrent Cervical Cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.10.007_bib0195","doi-asserted-by":"crossref","first-page":"S726","DOI":"10.1016\/j.annonc.2021.08.1166","article-title":"723MO Tisotumab vedotin (TV)+carboplatin (Carbo) in first-line (1L) or+pembrolizumab (Pembro) in previously treated (2L\/3L) recurrent or metastatic cervical cancer (r\/mCC): Interim results of ENGOT-Cx8\/GOG-3024\/innovaTV 205\u00a0study","volume":"32","author":"Vergote","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2023.10.007_bib0200","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2\u00a0study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2023.10.007_bib0205","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3389\/fonc.2020.00914","article-title":"High-Risk HPV Oncoproteins and PD-1\/PD-L1\u00a0Interplay in Human Cervical Cancer: Recent Evidence and Future Directions","volume":"10","author":"Allouch","year":"2020","journal-title":"Front Oncol"},{"issue":"17","key":"10.1016\/j.bulcan.2023.10.007_bib0210","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158\u00a0Study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2023.10.007_bib0215","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with Cemiplimab in Recurrent Cervical Cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.bulcan.2023.10.007_bib0220","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I\/II CheckMate 358\u00a0Trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.10.007_bib0225","doi-asserted-by":"crossref","first-page":"v898","DOI":"10.1093\/annonc\/mdz394.059","article-title":"Efficacy and safety of nivolumab (Nivo)+ipilimumab (Ipi) in patients (pts) with recurrent\/metastatic (R\/M) cervical cancer: Results from CheckMate 358","volume":"30","author":"Naumann","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2023.10.007_bib0230","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2021.08.018","article-title":"Phase II study of the safety and efficacy of the anti-PD-1\u00a0antibody balstilimab in patients with recurrent and\/or metastatic cervical cancer","volume":"163","author":"O\u2019Malley","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.10.007_bib0235","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S0090-8258(22)01293-8","article-title":"Efficacy and safety of cadonilimab, an anti-PD-1\/CTLA4\u00a0bi-specific antibody, in previously treated recurrent or metastatic (R\/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)","volume":"166","author":"Wu","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"20","key":"10.1016\/j.bulcan.2023.10.007_bib0240","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2023.10.007_bib0245","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ijgc-2019-001135","article-title":"CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study","volume":"30","author":"Mayadev","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2023.10.007_bib0250","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-13-2440","article-title":"An Antibody\u2013Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors","volume":"74","author":"Breij","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2023.10.007_bib0255","doi-asserted-by":"crossref","unstructured":"Zhao X, Cheng C, Gou J, Yi T, Qian Y, Du X, et al. Expression of tissue factor in human cervical carcinoma tissue. Exp Ther Med [Internet]. 2018\u00a0Sep 11 [cited 2023\u00a0Mar 26]; Available from: http:\/\/www.spandidos-publications.com\/10.3892\/etm.2018.6723.","DOI":"10.3892\/etm.2018.6723"},{"issue":"1","key":"10.1016\/j.bulcan.2023.10.007_bib0260","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ygyno.2020.07.025","article-title":"Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2\u00a0SUMMIT basket trial","volume":"159","author":"Oaknin","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"22","key":"10.1016\/j.bulcan.2023.10.007_bib0265","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","article-title":"Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2023.10.007_bib0270","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2009.08.012","article-title":"A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184","volume":"116","author":"Mackay","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"15","key":"10.1016\/j.bulcan.2023.10.007_bib0275","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S1470-2045(15)00220-X","article-title":"Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2\u00a0trial","volume":"16","author":"Symonds","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2023.10.007_bib0280","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2017.05.033","article-title":"A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology\/Gynecologic Oncology Group study","volume":"146","author":"Chan","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2023.10.007_bib0285","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1177\/1756287216663073","article-title":"Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience","volume":"8","author":"Ruiz-Morales","year":"2016","journal-title":"Ther Adv Urol"},{"issue":"2","key":"10.1016\/j.bulcan.2023.10.007_bib0290","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2023.10.007_bib0295","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3892\/mmr.2014.2293","article-title":"Expression of growth-regulated oncogene-1, hepatocyte growth factor, platelet-derived growth factor-AA and soluble E-selectin and their association with high-risk human papillomavirus infection in squamous cell carcinoma of the uterine cervix","volume":"10","author":"Zhang","year":"2014","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.bulcan.2023.10.007_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/6594016","article-title":"Diagnosis and Prognostic Significance of c-Met in Cervical Cancer: A Meta-Analysis","volume":"2016","author":"Peng","year":"2016","journal-title":"Dis Markers"},{"issue":"1","key":"10.1016\/j.bulcan.2023.10.007_bib0305","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1038\/s41598-017-05977-8","article-title":"Blockade of Axl signaling ameliorates HPV16E6-mediated tumorigenecity of cervical cancer","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2023.10.007_bib0310","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","article-title":"Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma","volume":"37","author":"Jazaeri","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2023.10.007_bib0315","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-19-1513","article-title":"A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3","volume":"26","author":"Choi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.bulcan.2023.10.007_bib0320","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(20)30486-1","article-title":"Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2\u00a0trial","volume":"21","author":"Youn","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2023.10.007_bib0325","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ebiom.2019.03.069","article-title":"Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome","volume":"43","author":"Scholl","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bulcan.2023.10.007_bib0165","doi-asserted-by":"crossref","first-page":"103049","DOI":"10.1016\/j.ebiom.2020.103049","article-title":"Genetic markers and phosphoprotein forms of beta-catenin p\u03b2-Cat552\u00a0and p\u03b2-Cat675\u00a0are prognostic biomarkers of cervical cancer","volume":"61","author":"Scholl","year":"2020","journal-title":"EBioMedicine"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123004290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123004290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:38:34Z","timestamp":1757792314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123004290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0007455123004290"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.10.007","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Place des th\u00e9rapies innovantes dans la prise en charge des cancers du col de l\u2019ut\u00e9rus","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}